Project description
Improving risk management in biomaterials
Biomaterials play a revolutionary role in modern medicine, as they are used in medical applications to support, enhance, or replace damaged tissue or biological functions. However, when biomaterials come into contact with the human body, unforeseen adverse reactions such as inflammation or infections often occur. The EU-funded PANBioRA project aims to develop a modular platform to assess these risks at different aspects and length scales. This platform encompasses antibody response, cytotoxicity/genotoxicity at the cellular level, as well as systemic and local effects at the tissue and organ-on-a-chip level. By enabling a time- and cost-effective risk assessment of new biomaterials in both healthy and disease states, this project aims to minimise side effects and enhance clinical outcomes, thereby reducing costs and time in healthcare.
Objective
PANBioRA aims at providing a comprehensive solution for the time- and cost-effective risk assessment of i) new biomaterials under health or disease states or ii) a given biomaterial for each patient in a personalized manner. It will standardize the evaluation of biomaterials and open the venue for pre-implantation, personalized diagnostics for biomaterial based applications.
PANBioRA will provide a modular platform to assess risks at different aspects and length scales. This comprises antibody response, cytotoxicity/genotoxicity at cell level, systemic and local effects at tissue and connected tissues (organ-on-a-chip) level. Moreover, physicochemical and biomechanical characterisation as well as predictive modelling at systems level will complement the system. This will be achieved by connecting testing modules in a structure supported by web-based modelling and risk radar tools together with a biomechanical testing system.
The platform will incorporate standardized protocols yielding significantly more information than the current methods for biomaterial risk assessment. Its accuracy will be demonstrated using known reference materials and validated in a pre-clinical setting.
PANBioRA will for the first time, predict the patient specific response to a given biomaterial before its implantation. This measure will allow for the selection of the best suitable material, minimizing side effects and improving health outcomes.
It will also accelerate the process of validation of the biocompatibility of new devices by providing an automated, comprehensive process for the parallel assessment of risks at different scales aiding new biomaterial discovery and commercialisation.
Altogether, PANBioRA will lead to a substantial economic impact due to a reduction of the amount of tests, decrease in healthcare costs due to complications. It will provide the necessary tools proper risk management related to biomaterials.
Fields of science
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensors
- engineering and technologymaterials engineeringcoating and films
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsradio technologyradar
- engineering and technologyother engineering and technologiesmicrotechnologyorgan on a chip
- engineering and technologyindustrial biotechnologybiomaterials
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
70176 Stuttgart
Germany
See on map
Participants (19)
D11KXN4 Glasnevin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
10100 Praha
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
12618 Tallinn
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
04103 Leipzig
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
12618 Tallinn
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
75011 Paris
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
34000 Kragujevac
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
70599 Stuttgart
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
75015 PARIS 15
See on map
1410 Waterloo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
02150 Espoo
See on map
1000 Tirana
See on map
NG7 2RD Nottingham
See on map
28006 Madrid
See on map
9 Dublin
See on map
75654 Paris
See on map
4000 Liege
See on map
Participation ended
67000 Strasbourg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
67100 Strasbourg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.